Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
CN¥37.24 - CN¥57.53
Next Earnings Date
Aug 20 2025 (Estimate)
Next Earnings Date
Aug 20 2025 (Est.)
Latest price
Market Cap | CN¥325.11B |
EV | CN¥300.70B |
Shares Outstanding | 6.36B |
Beta | 0.43 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | CN¥62.96 |
P/E 2025E | 48.09x |
P/Revenue 2025E | 10.62x |
Revenue | 2.60% |
EPS | 12.10% |
Operating Cash Flow | 20.70% |
Free Cash Flow | 28.70% |
Revenue | 12.60% |
EPS | 14.50% |
Operating Cash Flow | 9.40% |
Free Cash Flow | 20.00% |
Gross Margin 2025E | 85.95% |
Net Profit Margin 2025E | 22.13% |
ROE 2025E | 13.71% |
ROCE 2024 | 14.74% |
DPS 2025E | CN¥0.23 |
Payout Ratio 2025E | 21.70% |
Div. Yield 2025E | 0.45% |
DPS Last 3Y CAGR | 7.70% |
Price
%
1M
3M
6M
1Y
3Y
5Y
Jiangsu Hengrui Medicine Co., Ltd.
600276
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dai, Hong Bin
Employees
20,238
Website
www.hrs.com.cnIPO Date
2000-10-18
Headquarters
No. 38, Huanghe Road, Economic and Technological Development Zone, Lianyungang, Jiangsu Province, 222000, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved